Search all trials

Find therapies in clinical trials near you – page 6

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Malignant melanoma+4

Not recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Autogene Cevumeran

Contact Research Centre

Malignant melanoma+7

Not recruiting

Registered drug

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Binimetinib

Contact Research Centre

Malignant melanoma+7

Not recruiting

Registered drugNo placebo

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Binimetinib

Contact Research Centre

Malignant melanoma+2

Not recruiting

Registered drugNo placebo

Study of LN-144 and LN-145 (Tumor Infiltrating Lymphocytes) in patients with solid tumors, including melanoma, head and neck cancer, and non-small cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Aldesleukin

Contact Research Centre

Malignant melanoma+1

Not recruiting

InvestigationalNo placebo

Study on the Effectiveness and Safety of Naporafenib Combinations in Patients with Previously Treated Unresectable or Metastatic Melanoma

InvestigationalNo placebo

Belgium

Participants:0–17 years · 18–64 years · 65+ years
Substances:Naporafenib

Contact Research Centre

Malignant melanoma+1

Not recruiting

Registered drugNo placebo

Study Comparing Ipilimumab and Nivolumab with Standard Nivolumab for Patients with Stage III Melanoma

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Ipilimumab

Contact Research Centre

Malignant melanoma

Not recruiting

Registered drugNo placebo

Study on the Effectiveness of Pembrolizumab and Lenvatinib for Patients with Resectable Mucosal Melanoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lenvatinib

Contact Research Centre

Malignant melanoma+14

Not recruiting

InvestigationalNo placebo

Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

InvestigationalNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Incb099280

Contact Research Centre

Malignant melanoma

Not recruiting

Registered drug

Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Mrna-4157

Contact Research Centre

Malignant melanoma

Not recruiting

Registered drug

Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

Registered drug

Belgium

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Malignant melanoma

Not recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Pembrolizumab, Vibostolimab, and Lenvatinib for Patients with PD-1 Refractory Melanoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Lenvatinib

Contact Research Centre

Malignant melanoma

Not recruiting

Registered drugNo placebo

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Nivolumab

Contact Research Centre

Find therapies in clinical trials near you – page 6

79 trials match your criteria

Malignant melanoma+4

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Malignant melanoma+7

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Malignant melanoma+7

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Malignant melanoma+2

Study of LN-144 and LN-145 (Tumor Infiltrating Lymphocytes) in patients with solid tumors, including melanoma, head and neck cancer, and non-small cell lung cancer

Malignant melanoma+1

Study on the Effectiveness and Safety of Naporafenib Combinations in Patients with Previously Treated Unresectable or Metastatic Melanoma

Malignant melanoma+1

Study Comparing Ipilimumab and Nivolumab with Standard Nivolumab for Patients with Stage III Melanoma

Malignant melanoma

Study on the Effectiveness of Pembrolizumab and Lenvatinib for Patients with Resectable Mucosal Melanoma

Malignant melanoma+14

Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

Malignant melanoma

Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

Malignant melanoma

Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

Malignant melanoma

Study on the Safety and Effectiveness of Pembrolizumab, Vibostolimab, and Lenvatinib for Patients with PD-1 Refractory Melanoma

Malignant melanoma

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.